Long Title: Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in the Prevention of Disability at 3 Months in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion

Trial Profile

Long Title: Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in the Prevention of Disability at 3 Months in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Tenecteplase (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms TEMPO-2
  • Most Recent Events

    • 19 Feb 2016 Trial design presented at the 41st International Stroke Conference
    • 13 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 01 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top